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Brincidofovir (BCV) has broad-spectrum in vitro activity against dsDNA viruses, including smallpox, and
is being developed as a treatment for smallpox as well as infections caused by other dsDNA viruses. BCV
has previously been shown to be active in multiple animal models of smallpox. Here we present the
results of a randomized, blinded, placebo-controlled study of the efﬁcacy and pharmacokinetics of a
novel, ‘‘humanized’’ regimen of BCV for treatment of New Zealand White rabbits infected with a highly
lethal inoculum of rabbitpox virus, a well characterized model of smallpox. Compared with placebo, a
dose-dependent increase in survival was observed in all BCV-treatment groups. Concentrations of cido-
fovir diphosphate (CDV-PP), the active antiviral, in rabbit peripheral blood mononuclear cells (PBMCs)
were determined for comparison to those produced in humans at the dose proposed for treatment of
smallpox. CDV-PP exposure in PBMCs from rabbits given BCV scaled to human exposures at the dose
proposed for treatment of smallpox, which is also currently under evaluation for other indications. The
results of this study demonstrate the activity of BCV in the rabbitpox model of smallpox and the feasi-
bility of scaling doses efﬁcacious in the model to a proposed human dose and regimen for treatment
of smallpox.
 2015 The Authors. Published by Elsevier B.V. This is an open access articleunder the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
Brincidofovir (BCV) is an orally-administered lipid conjugate of
cidofovir (CDV, Vistide) that was designed to avoid the renal accu-
mulation and associated toxicity of CDV, promote oral bioavailabil-
ity, and improve general distribution and intracellular delivery of
the active antiviral, CDV-diphosphate (CDV-PP). BCV is active
against all 5 families of dsDNA viruses that cause human disease
with improved potency, by several orders of magnitude, compared
with cidofovir (Lanier et al., 2010). In Phase 1 clinical trials, BCV
was well tolerated and orally bioavailable with linear, dose propor-
tional pharmacokinetics over the dose range of 0.025–2 mg/kg
(Painter et al., 2012). BCV is currently in Phase 3 clinical develop-
ment for the prevention of CMV (CMX001-301; NCT01769170)
and treatment of adenovirus infections (CMX001-304;
NCT02087306). To date, more than 1000 human subjects havebeen administered BCV with no evidence of cidofovir-like
dose-limiting nephrotoxicity.
Intradermal inoculation of New Zealand White rabbits with a
highly lethal inoculum of rabbitpox virus (RPXV) is a well charac-
terized model of smallpox (Adams et al., 2007). The scientiﬁc
community and FDA have recognized this model as appropriate
for evaluation of potential smallpox therapeutics because it repro-
duces key human disease characteristics including high lethality
with a low inoculum, an incubation period leading to disseminated
disease, and clinical signs of disease including fever, viremia, and
secondary skin lesions (Tran and Cargill, 2011). Preliminary studies
demonstrated the antiviral activity of BCV in the RPXV model for
post-exposure prophylaxis as well as treatment of active infection
(Lanier et al., 2010; Rice et al., 2011a,b). When treatment was ini-
tiated 1 day prior to infection with a lethal inoculum of RPXV, all
animals administered BCV at a dose of 10 mg/kg/day for 5 days
survived. Similarly, BCV prevented mortality when given late in
the infection cycle, after the appearance of clinical signs of the dis-
ease (fever and lesions). Rabbits administered 10 mg/kg/day BCV
for 5 days beginning either 4 or 5 days after infection with a lethal
inoculum of RPXV exhibited 100 and 75 percent survival,
Table 1
Summary of study design.
Group Number randomizeda BCV dose 1st/2nd/3rd
(mg/kg)
Timing of dose administration
First dose Second dose Third dose
1 16 (7M/9F) 5/5/5 At or within 4 h of 1st
observation of 2 lesions
At 1st observation of 2
lesions plus 48 (±4) h
At 1st observation of 2
lesions plus 96 (±4) h2 15 (10M/5F) 20/5/5
3 15 (8M/7F) 20/20/20
4 16 (6M/10F) 0/0/0
5 (PK) 9 males 20/5/5 Day 4 post infection 48 (±4) h after ﬁrst dose 96 (±4) h after ﬁrst dose
PBMC PK sampling
(hours post-dose):
12, 24, 48 N/A Predose, 24, 48, 72, 120 and 168
a The target minimum randomization was 6/sex/group. Randomization day was based on ﬁrst observation of lesions in each animal.
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of lesions conferred a statistically signiﬁcant survival beneﬁt com-
pared with placebo (Rice et al., 2011a,b).
The goals for the present study were to (1) show that perfor-
mance of the intradermal RPXV model is robust and consistent
by transferring it from the academic lab where it was developed
to an independent contract laboratory facility; (2) identify an opti-
mized dose for evaluation in a pivotal efﬁcacy study; and (3) assess
the efﬁcacy and pharmacokinetic (PK) proﬁle of a novel, ‘‘human-
ized’’ dose of BCV based on doses estimated to produce exposures
in rabbits that were equivalent to or lower than exposures in
humans given doses under evaluation for other indications (CMV
and AdV). Accordingly, NZW rabbits were infected with a highly
lethal inoculum of a puriﬁed and well characterized stock of
RPXV under rigorous laboratory conditions in which all study per-
sonnel were blinded to treatment assignment and treatment was
initiated in each animal individually after appearance of secondary
skin lesions at a site remote from the inoculation site.
2. Materials and methods
2.1. Production, puriﬁcation, and characterization of the challenge
agent
Plaque puriﬁed RPXV Utrecht strain master stock was obtained
from Richard W. Moyer (University of Florida College of Medicine,
Gainesville, FL) and expanded in CV-1 cells to produce a single
RPXV lot (Southern Research Institute, Frederick, MD). CV-1 cells
were maintained in Minimal Essential Medium supplemented with
non-essential amino acids, L-glutamine, penicillin/streptomycin
and 10% fetal bovine serum. The RPXV virus was puriﬁed over a
36% sucrose cushion, suspended in PBS, and stored at 80 C. The
working stock was titrated by plaque assay, yielding a concentra-
tion of 5.8  109 plaque forming units (PFU)/mL. Speciﬁcation test-
ing was conducted including sterility, pH, endotoxin level,
mycoplasma, bovine viral diarrhea virus (BVDV), and DNA
sequence comparison. No growth was detected in sterility testing,
pH was determined to be 6.14, endotoxin levels were determined
to be 7.27 EU/mL at a 1:500 dilution, and the stock was negative
for mycoplasma and BVDV. The stock material was conﬁrmed
RPXV by matching a target DNA sequence (hemagglutinin gene
region; bases 167066–168003) with GenBank accession number
AY484669.
2.2. Test facility, housing and study assignment of animals
The study was conducted at Battelle Biomedical Research
Center (West Jefferson, OH). Seventy-one, 7 week + 3 day-old
Myrtle’s lineage NZW rabbits (Covance, Princeton, NJ) were
single-housed in standard rabbit caging and acclimated for 7 days
in the study room. Fluorescent lighting (12 h cycle), study room
temperature, and humidity were maintained according toBattelle SOPs. Rabbits were fed Certiﬁed Rabbit Chow (PMI, St.
Louis, MO) and had ad libitum access to water. During the acclima-
tion period animals were observed twice daily for clinical signs,
body weights were recorded for randomization purposes and each
animal was implanted with 2 subcutaneous temperature transpon-
ders (shoulder/back and rump/hip areas). The back of each animal
was shaved to aid monitoring for secondary lesions. All animals
were examined by a study veterinarian and conﬁrmed to be in
good health before release to the study. Animals were randomized
by weight to select 9 rabbits for inclusion in the PK arm of the
study (Group 5). The remaining 62 animals were assigned to
the efﬁcacy arm of the study in a 1:1:1:1 blinded fashion upon
the presentation of secondary lesions after infection with RPXV
(Groups 1–4). The overall study design is summarized in Table 1.2.3. Inoculation, lesion monitoring prior to randomization and
monitoring following randomization until termination
On Day 0, all 71 rabbits were infected with a target inoculum of
300 PFU of RPXV stock diluted in Dulbecco’s phosphate buffered
saline (DPBS). The concentration of stock virus dilutions used for
challenge was determined within 4 h after inoculation by plaque
assay to conﬁrm the actual challenge dose (ie back titer).
Inoculation was performed according to Battelle SOPs. Brieﬂy,
animals were anesthetized by intramuscular injection of ketami-
ne/xylazine (22–50 mg/kg and 3–10 mg/kg, respectively). The chal-
lenge dose was divided in half and all animals were inoculated by
bilateral intradermal injections in each thigh region (approximate-
ly 100 lL/thigh). The area of injection on both thighs was shaved,
wiped with isopropanol and allowed to air dry prior to inoculation.
Infected rabbits were housed in animal rooms within Biosafety
Level 3 (BSL3) containment.
Beginning at inoculation, all animals were monitored 3 times
daily for the presence of secondary pox lesions. Animals in the
efﬁcacy arm met randomization criteria when observed with sec-
ondary pox lesions anywhere on the body other than the primary
site of inoculation. Randomization criteria required the observa-
tion of lesions to be conﬁrmed by a second technician prior to ran-
domization. Following randomization, lesion counts were
performed once daily. The areas monitored included the ears, back,
mouth, nose, eyes, footpads, and ano-genital area. Animals were
also monitored for clinical signs of disease (mortality and signs
of ill health including respiratory changes) twice daily until the
scheduled termination of the study. Body weights, body tem-
peratures, and respiration rates were recorded daily and compared
to baseline values obtained during the acclimation period. PK ani-
mals (Group 5) were not monitored for lesions, but had clinical
observations performed twice daily after inoculation.
Surviving efﬁcacy study animals were euthanized on Day 42
after randomization. Surviving PK study animals were euthanized
as scheduled 72, 120, and 168 h following administration of the
last dose. The decision to euthanize an animal prior to the
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based upon disease progression according to a protocol-speciﬁed,
predetermined set of euthanasia criteria that included respiratory
distress (typically open mouth breathing), general morbidity or
signiﬁcant changes in respiration rate, body temperature, or body
weight. Following completion of the in-life phase of the study,
mortality and lesion data underwent quality control, technical
review, and quality assurance review.
2.4. Dose administration
Dosing kits containing BCV or placebo were prepared by
Chimerix Inc. (Durham, NC). The kits, containing 3 vials labeled
with the kit and dose numbers, were shipped to BBRC and stored
at approximately 4 C prior to use. Conﬁrmatory dose formulation
analysis was performed by Intertek Pharmaceutical Services
(Whitehouse, NJ). Doses were administered by oral feeding of the
formulation through a syringe. Rabbits were trained to accept oral
administration of the dosing solution (20% w/v sucrose) on 5 occa-
sions prior to RPXV inoculation. The total dose administered to
each animal and whether there was any discernible loss was noted.
The dose formulation was colored blue to aid this observation.
In the efﬁcacy study (Groups 1–4), the ﬁrst dose of each treat-
ment was administered within 4 h of randomization. Animals were
randomized and assigned dosing kits in the order in which they
presented with lesions. The second and third doses of each treat-
ment were administered at approximately 48 (±4) and 96 (±4) h
after the ﬁrst dose. Rabbits in Groups 1–4 received doses of
5/5/5, 20/5/5, 20/20/20, or 0/0/0 (placebo) mg/kg BCV, respectively.
The 20/5/5 mg/kg dose was a humanized dose on the anticipated
exposure in rabbits. It was derived using PK data from previous
studies in rabbits and humans. All test facility personnel were
blinded to the treatment assignment of each main study animal.
In the PK arm (Group 5), the ﬁrst dose of BCV was administered
to all animals on Day 4 after RPXV inoculation. Dosing was initiat-
ed in all PK animals simultaneously in order to facilitate timed
blood collections. The second and third doses were administered
at approximately 48 (±4) and 96 (±4) h after the ﬁrst dose.
Rabbits in Group 5 received only the 20/5/5 mg/kg humanized
BCV treatment regimen. Test facility personnel were not blinded
to the treatment assignment of the PK animals (Group 5), therefore
they were not included in the primary efﬁcacy analysis.
2.5. Viremia
Blood RPXV titers were determined for all efﬁcacy animals
(Group 1–4) by a pan-orthopox virus, hemagglutinin (HA-J7R)
gene-speciﬁc qPCR assay prior to inoculation on Day 0 and 2, 4,
6, 8, 10, 15, 30, and 42 days after randomization. Rabbits were
sedated with acepromazine (1 mg/kg, IM) and blood obtained from
the ear vein or artery. Terminal blood samples were collected by
cardiac puncture. Nucleic acids were isolated from 100 microliters
of whole blood using the Speciﬁc B protocol on a NucliSens
EasyMAG instrument (bioMérieux, Durham, NC) and eluted into
a ﬁnal volume of 40 microliters. RPXV DNA was quantiﬁed using
a HA-J7R speciﬁc probe set as previously described (Kulesh et al.,
2004).
2.6. Resistance monitoring
Blood for determination of genotypic resistance to BCV was col-
lected from efﬁcacy animals (Groups 1–4) at regular intervals
beginning 6 days after randomization and continuing until the
scheduled termination of the study. Positive control specimens
were prepared by spiking naïve rabbit blood to a ﬁnal concentra-
tion of 2000 and 20,000 PFU/mL RPXV. Nucleic acids were isolatedfrom 100 lL of whole blood for each sample and positive control
sample using the Speciﬁc B protocol on an EasyMAG instrument
(bioMérieux, Durham, NC) and eluted into a ﬁnal volume of
40 lL. Nucleic acid specimens were shipped to SeqWright (Houston
TX) for sequencing of the RPXV polymerase gene. The virus geno-
type from treated and placebo control animals was compared to
the genotype of the consensus sequence for challenge virus.
2.7. Assessment of immune response
The plaque reduction neutralization titer (PRNT) assay was per-
formed in order to detect and quantify neutralizing antibodies to
RPXV virus in rabbit serum (Battelle SOP Number BBRC. X-245),
and determine the effect of treatment with BCV or placebo. Blood
for PRNT testing was collected from efﬁcacy animals (Groups
1–4) 6, 10, 15, 30 and 42 days after randomization until the sched-
uled termination of the study.
2.8. Pharmacokinetic assessments
Blood samples (8 mL) from PK animals (Group 5) were collect-
ed, PBMCs isolated, and the concentration of CDV-PP determined
using a validated analytical method. Blood was collected from 3
animals at 12, 24, and 48 h after the ﬁrst dose, immediately prior
to the last dose (dose 3), and 24, 48, 72, 120 and 168 h after the last
dose. Per IACUC limits, each rabbit was sampled three times; twice
prior to termination and at termination with a minimum of 72 h
between each sampling. Rabbits were sedated for blood collection.
PBMCs were isolated using Vacutainer CPT™ cell preparation
tubes with sodium citrate anticoagulant (BD, Franklin Lakes, NJ).
Blood samples were mixed and centrifuged in CPT tubes at 21 C
and 1750 RCF for 20 min. The PBMC layer was extracted, washed
with PBS, counted, ﬁxed in 125 lL of 7:3 (v/v) methanol–water
and stored at 70 C prior to analysis. The concentration of
CDV-PP in PBMC lysate was determined (Pyxant Labs Inc.,
Colorado Springs, CO). CDV-PP and its stable-labeled isotope
(CDV(1,3-15N-2,4,6-13C-cytosine)-PP) (Chemcyte, Inc., San Diego,
CA), used as an internal standard, were analyzed by LC/MS/MS uti-
lizing electro spray ionization in the positive ionization mode and
anionic exchange chromatography. Raw picogram amounts of
CDV-PP were calculated and converted to pg/106 PBMCs using
the individual cell count for each sample.
Because each rabbit was only sampled three times during the
dose administration period, the PK analysis was a single composite
proﬁle based uponmean concentrations of CDV-PP. Concentrations
below the lower limit of quantitation were set to 0 except where
all values at a given time were BLQ, in which case the mean result
was BLQ. Non-compartmental analysis was completed using
WinNonlin Version 6.3 (Cetara, St. Louis, MO).
2.9. Statistical analysis
Time-to-death data combined with survival data were analyzed
to identify differences in protection for the treatment groups com-
pared with the placebo group. The Kaplan–Meier curves were plot-
ted and the log-rank test was computed to compare each
treatment group to placebo. Two-sided Fisher’s exact tests were
performed to compare the survival rates between each treatment
group and the placebo group. T-tests were used to compare the
change in viral load from baseline in each BCV treatment group
with placebo for each post-randomization day on which samples
were obtained. Fisher’s exact test was used to compare survival
between BCV and placebo-treated groups on each day randomized
post-inoculation. Unless stated otherwise, the term ‘‘signiﬁcant’’ is
used to denote the results of pairwise comparisons that were
signiﬁcant at the 0.05 level.
Fig. 1. Survival of RPXV-infected rabbits randomized to one of 3 different regimens
of BCV or placebo. A total of 62 rabbits were infected intradermally with a target
inoculum of 300 PFU RPXV on Day 0, randomized into treatment groups after the
appearance of secondary lesions, and administered 3 doses of placebo or BCV with
48 h between doses. One 5/5/5 mg/kg animal was mis-dosed and excluded from the
analysis. Group assignments included placebo (N = 16), 5/5/5 mg/kg BCV (N = 15),
20/5/5 mg/kg BCV (N = 15), and 20/20/20 mg/kg BCV (N = 15). Kaplan–Meier curves
were generated to depict the proportion of surviving rabbits on each day of the
study until the scheduled termination 42 days after randomization. BCV treatment
increased survival at low, loading/maintenance, and high doses (p = 0.270, 0.012,
and 0.004, respectively). Asterisks indicate signiﬁcance at p < 0.05.
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3.1. Model performance: inoculation, subjects meeting randomization
criteria, observation and progression of clinical signs of disease
Back-titer analysis conﬁrmed the actual inoculum was
187 PFU/mL. All animals were successfully inoculated and all 62
rabbits in the efﬁcacy arm of the study (Groups 1–4) met random-
ization criteria either 3, 4 or 5 days post-infection. One rabbit ran-
domized to 5/5/5 mg/kg was mis-dosed and subsequently removed
from all analyses. Body weights were recorded at regular intervals
during the study and compared with baseline (pre-inoculation)
values. In general, signiﬁcant decreases in mean body weight were
observed 8–10 days following inoculation in BCV-treated animals
with a slight trend toward greater weight loss at lower doses (data
not shown). The weight loss extended through Day 14
post-inoculation in placebo treated animals. All surviving animals
in all groups showed signiﬁcant increases in body weight relative
to baseline after Day 14 until the scheduled termination of the
study. These results are consistent with previously published
reports (Adams et al., 2007; Rice et al., 2011a).
Signiﬁcant increases in body temperature were generally
observed between Days 3 and 9 post-infection after which they
gradually abated (data not shown). Fever, as deﬁned by a 1.5F
increase in body temperature from the mean baseline value for
each animal, was observed in 87.5% of rabbits on Day 3 and 100%
of rabbits by Day 4. Body temperatures returned to normal in all
groups by about Day 14 post-infection and remained normal for
the duration of the study. These results are similar to those report-
ed previously (Adams et al., 2007; Rice et al., 2011a). Signiﬁcant
changes in respiration rate relative to baseline occurred intermit-
tently through the scheduled termination of the study. There was
a trend in all animals suggestive of decreased respiration rate, most
apparent 8 days post-infection before gradually increasing to Day
14 post-infection after which they were fairly constant. Mean
respiration rates were generally indistinguishable between groups
(data not shown).3.2. BCV treatment increased the survival of RPXV-infected rabbits in a
dose-related manner
Animals found dead or euthanized prior to the scheduled termi-
nation exhibited symptoms typical of severe RPXV disease includ-
ing fever, lesions and respiratory abnormalities. The survival rates
for the placebo, 5/5/5, 20/5/5, and 20/20/20 mg/kg BCV treatment
groups were 25%, 47%, 73%, and 80%, respectively. Both the
20/5/5 and 20/20/20 mg/kg BCV groups had a signiﬁcantly higher
rate of survival compared with the placebo treated group
(p = 0.012 and 0.004, respectively). The time-to-death and survival
data are presented by Kaplan–Meier plot in Fig. 1. All deaths were
attributed to RPXV disease.3.3. BCV treatment decreased the viral load of RPXV-infected rabbits in
a dose-related manner
Following inoculation, viral nucleic acid in peripheral blood was
quantiﬁed by qPCR targeting a pan-orthopox virus hemagglutinin
(HA-J7R) gene. Data were analyzed as the change from baseline
viremia at randomization with the last observation carried forward
for animals that died prior to the scheduled study termination. As
expected, the majority of animals that survived to the scheduled
termination exhibited viral DNA levels at or below the lower limit
of quantitation of the qPCR assay regardless of treatment group.
Overall, there was a dose-related decrease in mean viral load in
rabbits administered BCV compared with those administeredplacebo (Fig. 2). The difference was apparent by Day 6
post-randomization at which time viral load was decreased across
all BCV treatment groups and signiﬁcantly in the 20/5/5 mg/kg and
20/20/20 mg/kg dose groups (p < 0.05). The BCV-responsive and
dose-related decrease in viral load correlated with survival across
treatment groups compared with placebo.
3.4. Lack of resistance and formation of protective immunity
A total of 63 puriﬁed nucleic acid samples (61 test samples and
2 positive controls) were shipped to SeqWright for sequencing of
the RPXV polymerase gene. Consensus sequences were compared
against the reference standard provided by Battelle. All samples
were found to be 100% identical to the provided reference
sequence within the region ampliﬁed. Following inoculation,
development of neutralizing antibody to RPXV was monitored in
serum by the PRNT assay. Results of ANOVA models comparing
group geometric mean PRNT values for each study day are located.
Neutralizing antibodies were not present for any animal prior to
study start. All study groups developed neutralizing antibodies fol-
lowing challenge with RPXV. Titers increased by approximately
20-fold over the course of the study. However, there were no sig-
niﬁcant differences between mean PRNT values of the groups at
any of the study days examined.
3.5. Earlier treatment with BCV resulted in improved survival
All 62 animals in the efﬁcacy arm met the randomization crite-
ria for dosing, however, the day secondary lesions were ﬁrst
observed varied, and therefore, animals were randomized on dif-
ferent days following inoculation: 24 animals on Day 3, 19 animals
on Day 4, and 19 animals on Day 5 post-infection. The rate of sur-
vival in placebo treated rabbits was consistent regardless of the
Fig. 3. Percent mortality of RPXV-infected rabbits treated with placebo or BCV by
day randomized. RPXV-infected rabbits were randomized to treatment with either
placebo or BCV at the ﬁrst observation of secondary lesions. Approximately equal
numbers of rabbits met randomization criteria on Days 3, 4 or 5 following RPXV
inoculation (represented by black, red, and green bars, respectively). All 3 BCV
treatment groups were pooled for this analysis. Mortality of 67%, 75%, and 83% was
observed in placebo treated groups randomized on Day 3, 4, or 5. Mortality of 12%,
33%, and 62% was observed in BCV-treated groups randomized on Day 3, 4, or 5.
Early randomization to BCV treatment resulted in improved survival compared
with animals randomized late in the disease course. Asterisks indicate signiﬁcance
at p < 0.05.
Fig. 2. Change in RPXV viral load from baseline in rabbits treated with BCV
compared with placebo. Poxvirus nucleic acid in circulating blood was quantiﬁed by
qPCR targeting the hemagglutinin (HA-J7R) gene in RPXV-infected rabbits treated
with placebo or one of three regimens of BCV (5/5/5, 20/5/5, or 20/20/20 mg/kg
each at 48 h intervals). Data are presented as the (log10) change from baseline
viremia determined for each animal at randomization with the last observation
carried forward for any animals that died prior to the scheduled study termination.
There was a dose-related decrease in viral load in rabbits administered BCV
compared with those administered placebo. The limit of detection of the qPCR assay
was 6.70  103 gene copies/mL. Asterisks indicate signiﬁcance at p < 0.05.
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median time to death of 8 days post-infection (Fig. 3). By contrast,
the rate of survival in BCV-treated rabbits was highly correlated
with the day of randomization. Pooling animals in all 3 BCV
treatment groups, 88% overall survival was observed among
BCV-treated rabbits randomized on Day 3 post-infection. Survival
decreased to 67% among animals randomized on Day 4
post-infection and, for animals randomized on Day 5
post-infection survival, was indistinguishable from placebo.
Logistic regression analysis of survival as a function of both treat-
ment group and day of initiation of treatment after inoculation
conﬁrmed that effects of both the dose and day of treatment ini-
tiation were signiﬁcant to survival (p = 0.0147 and p = 0.0296,
respectively).
3.6. Exposure to the active antiviral metabolite, CDV-PP, in PBMCs of
rabbits administered an efﬁcacious dose regimen of 20/5/5 mg/kg were
equivalent to or lower than exposures in humans given the doses
currently proposed for treatment of smallpox
All 9 rabbits in the PK arm of the study received a three-dose
regimen of 20/5/5 mg/kg BCV initiated on Day 4 post-infection.
This humanized dose regimen was derived using PK data from
previous rabbit and human studies conducted by Chimerix to
support regulatory submissions. The humanized dose was intend-
ed to produce exposures in rabbits equal to or lower than those
produced in humans given BCV at the dose evaluated for preven-
tion or treatment of other dsDNA virus infections. One animal in
the PK arm died on Day 7 post-infection due to RPXV disease. As
a result, the 48 and 168 h samples following dose 3 were not
obtained from this animal. All other rabbits in the PK arm survived
to the scheduled termination and all PBMC samples were collected
successfully. Concentrations of CDV-PP in PBMCs following theﬁrst (20 mg/kg) and last (5 mg/kg) doses were determined and
all concentration data were used in the PK analysis.
Because CDV-PP is produced by phosphorylation of cidofovir
inside cells, the matrix is PBMC cells and the results are presented
adjusted for cell count. The peak concentration, Cmax, was
3.99 pg/106 cells, occurring 24 h after the ﬁrst dose, and
14.5 pg/106 cells, occurring 48 h after the last dose. Following the
ﬁrst and last doses, the extent of exposure, AUC0-48, was
136 pg⁄h/106 cells and AUC0-168 was 795 pg⁄h/106 cells. The
half-life (t1/2) of CDV-PP was estimated to be 30 h. Plasma concen-
trations of BCV, also essential for scaling to a human dose, were not
determined in this study because the blood volume required for
PBMC isolation and analysis prohibited the requisite blood sam-
pling. Previous studies, however, demonstrated that plasma expo-
sure (Cmax and AUC) to BCV in rabbits given doses of 20 mg/kg is
lower than exposure in humans given a dose of 200 mg, the dose
proposed for treatment of smallpox (Lanier et al., 2010; Tippin
et al., in preparation). Therefore, the focus of the PK arm of this
study was limited to determination of PBMC CDV-PP
concentrations.
A discussion of the pharmacokinetic results in rabbits and their
use in conjunction with human pharmacokinetic data to scale to a
proposed human dose for treatment of smallpox is provided as a
Supplemental attachment to this research report.4. Discussion
In the absence of the ability to conduct traditional clinical trials,
the FDA has provided a path for development of antivirals for treat-
ment of smallpox under the ‘‘animal rule’’ using efﬁcacy data
generated in well characterized animal models of smallpox togeth-
er with human safety data. While no single animal model repro-
duces all clinical features of smallpox, the intradermal RPXV
model in rabbits shares many key features of smallpox that make
it an excellent model for use in evaluating potential therapeutics.
New Zealand White rabbits are a standard laboratory species with
well controlled historical lineages and bred to be speciﬁc pathogen
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evaluation of PK and clinical endpoints but also permits large,
well-powered studies for meaningful statistical analysis.
Working in collaboration with scientists at the University of
Florida, we characterized the intradermal RPXV model and per-
formed pilot studies with BCV before transferring the model to a
contract research organization for independent testing. The design
of the current study was informed predominantly by 3 blinded,
placebo-controlled studies performed in Florida showing increas-
ing beneﬁt of treatment with BCV using a 1, 2 or 3 dose regimen
(Rice et al., 2011a). In those studies even a single dose of 20 mg/kg
BCV provided a statistically signiﬁcant survival beneﬁt in the RPXV
model when treatment was initiated in individual animals after
observation of clinical signs of disease. Although a dose of
20 mg/kg is higher on a weight adjusted basis compared to the pro-
posed human dose for treatment of smallpox (200 mg or
approximately 1.5– 3 mg/kg), the favorable PK proﬁle of BCV in
humans results in higher exposures at lower doses.
In the current study, we evaluated the efﬁcacy of three potential
regimens of BCV including a ‘‘humanized’’ regimen consisting of an
induction dose of 20 mg/kg followed by two maintenance doses of
5 mg/kg in the intradermal RPXV model. The results of this study
demonstrated that this 3 dose regimen, with administrations
spaced at 48 h intervals and initiated individually at the ﬁrst obser-
vation of secondary lesions, resulted in a signiﬁcant survival bene-
ﬁt compared to rabbits treated with placebo. Although a trend
toward improved survival was observed at the 5/5/5 mg/kg dose,
the difference was not signiﬁcant compared to animals adminis-
tered placebo. Further, since survival was not meaningfully
improved in animals receiving the 20/20/20 mg/kg high dose regi-
men, the 20/5/5 mg/kg dose was concluded to be an optimized
dose and therefore appropriate for evaluation in a pivotal study
according to FDA guidance provided in the draft animal rule (U.S.
Food and Drug Administration, 2014).
Evaluation of the efﬁcacy of BCV based on the timing of ini-
tiation of treatment in relation to day of infection also informs
its clinical utility in a smallpox outbreak. In this study, rabbits were
randomized to blinded treatment after the ﬁrst observation of sec-
ondary lesions which was relatively evenly distributed on Days 3,
4, and 5 post-RPXV infection. Combining all BCV-treatment groups,
the mortality rate for animals that received BCV later in the disease
course, beginning on Day 5 post-infection, was signiﬁcantly higher
than those that initiated treatment on Day 3 post-infection.
Previous studies have shown a similar improvement in efﬁcacy
in this model when BCV is initiated in the absence of clinical signs
of disease based solely on proximity to infection (so called
post-exposure prophylaxis). These results are consistent with
those of previous studies of BCV both in the RPXV model and in
mouse models of smallpox, examining the effect of treatment ini-
tiated mid-way or later in the infection cycle (Parker et al., 2008;
Quenelle et al., 2004; Rice et al., 2011a,b). Overall, early diagnosis
and treatment with BCV is expected to correlate with improved
patient outcome, and treatment initiated at or beyond the
mid-point of disease may not be efﬁcacious.
Smallpox skin lesions are a clinically relevant trigger for ran-
domization since they were used historically to diagnose smallpox
(Fenner et al., 1988). Skin lesions are also a feature of RPXV disease
in rabbits. The ﬁrst observation of secondary lesions in the RPXV
model is variable, depending largely on the skill and training of
the technician making the observation. It has been reported to
occur as early as 2 days and as late as 7 days after inoculation while
the median day of death is more consistent, between 8 and 10 days
post-infection. The emergence of other signs of disease, speciﬁcally
fever and viremia, occurs earlier, on Days 2 to 3 post-infection and
more consistently (Chimerix unpublished data, Adams et al., 2007;Rice et al., 2011a,b). In the case of a smallpox outbreak, index cases
may be diagnosed only after presentation of these distinctive
lesions, especially due to its long absence from the clinic leading
physicians to be unfamiliar with its diagnosis. For secondary cases,
however, it’s likely that modern diagnostic tools (i.e., analysis for
smallpox virus in blood) will result in earlier diagnosis than the
observation of skin lesions used historically.
In humans, the characteristics of smallpox viremia are only
vaguely understood since the disease was eradicated prior to the
advent of modern molecular tools. Laboratory conﬁrmation of
smallpox viremia by qPCR prior to treatment, while preferable,
may be impractical in an outbreak affecting anything more than
a small number of patients. Fever, even though nonspeciﬁc, would
be highly relevant to diagnosis in a large outbreak when initiating
treatment as early in disease as possible is a high priority. The ebo-
la outbreak of 2014 is a relevant example of the use of fever for
diagnosis, not only in the resource deﬁcient countries where it
originated, but also in the handful of cases diagnosed outside the
African continent. Future analysis of viremia and fever will be used
to align initiation of treatment in the RPXV model with the expect-
ed clinical diagnosis and treatment of the majority of smallpox
patients.
The importance of early initiation of treatment is further
emphasized by the observation that the prognosis for recovery
from smallpox is dependent upon the ability of the host to quickly
mount an immune response. Therefore, BCV, which acts by inhibit-
ing viral replication, blunts peak viral load and improves survival
by providing more time for the host immune response. To this
end, it is important to note that data from this study indicates that
BCV does not interfere with the host immune response to infection.
The development of neutralizing antibodies to RPXV was moni-
tored throughout this study and it was found that antibody titers,
not present in any animal prior to infection, were present in all
rabbits who survived to the scheduled termination with no differ-
ence in titers between placebo and BCV-treated animals. This
observation is consistent with reports from other investigators that
BCV did not interfere with formation of protective immunity fol-
lowing infection or vaccination in the mouse ectromelia and vac-
cinia models (Parker et al., 2014; Zaitseva et al., 2015). Hence
patients infected with smallpox and treated with BCV would be
expected to develop full protective immunity against subsequent
smallpox infection.
In addition to the intradermal rabbitpox model, studies have
been conducted in the intranasal ectromelia (ECTV, mousepox)
model in mice, another model of smallpox that was developed in
a well characterized laboratory animal species; their small size
allowing the conduct of large, well-controlled, appropriately pow-
ered studies (Buller et al., 2004). In the mouse ectromelia model,
death occurs about 9 days after lethal infection. As was observed
in the RPXVmodel, a single dose of 20 mg/kg, which produces plas-
ma exposures to BCV in mice that are lower than those produced in
humans given current clinical doses of BCV, provided complete
protection from lethal ECTV infection when initiated as late as
4 days post-infection. Other studies demonstrated that dose regi-
mens employing repeated BCV administration provide complete
protection when initiated as late as 5 days post-infection (Parker
et al., 2008, 2009, 2010, 2012). In addition to the data supporting
the efﬁcacy of BCV in the intradermal RPXV model, these studies
in a second animal model add to the weight of evidence supporting
the likely efﬁcacy of BCV for treatment of smallpox.
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Appendix A. Supplementary data
Scaling from a dose and regimen efﬁcacious in the intradermal
rabbitpox model to a dose and regimen recommended for treat-
ment of smallpox. Supplementary data associated with this article
can be found, in the online version, at http://dx.doi.org/10.1016/j.
antiviral.2015.02.007.
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